NEW YORK, Sept 11 (Reuters) - Bristol-Myers Squibb Co stood by its $60-a-share offer for ImClone Systems Inc, a day after the biotechnology company spurned Bristol’s offer and said it had another bid at $70 a share.
NEW YORK, Sept 11 (Reuters) - Bristol-Myers Squibb Co stood by its $60-a-share offer for ImClone Systems Inc, a day after the biotechnology company spurned Bristol’s offer and said it had another bid at $70 a share.
